Please assess the completion status of the following clinical trial:

Trial Title: Dose Reduction of Lopinavir in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age from 2- 18 years old~* Documented positive test for HIV-1 infection~* PI-naïve~* HIV RNA viral load \> 1,000 copies~* Written informed consent~Exclusion Criteria:~* Active opportunistic infection~* Relevant history or current condition, illness that might interfere with drug absorption, distribution, metabolism or excretion.~* Use of concomitant medication that may interfere with the pharmacokinetics of lopinavir/ritonavir~* Pregnancy or lactating~* Inability to understand the nature and extent of the study and the procedures required.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Lopinavir/ritonavir standard dose + zidovudine and lamivudine
- 2 (Type: ACTIVE_COMPARATOR): Lopinavir/ritonavir low dose (70% of standard dose) + zidovudine and lamivudine

Based on this trial design, predict the completion outcome and termination type (if applicable).